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Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania dono-
vani and Leishmania infantum (Leishmania chagasi in the Americas). These Leishmania
species infect macrophages throughout the viscera, and parasites are typically found in
the spleen, liver, and bone marrow. Patients with active disease typically exhibit marked
immunosuppression, lack reactivity to the Leishmania skin test (LST), a delayed type hyper-
sensitivity test, and their peripheral blood mononuclear cells (PBMC) fail to respond when
stimulated with leishmanial antigens in vitro. However, most people infected with vis-
ceralizing species of Leishmania never develop disease. Understanding immune failure
and the underlying immune mechanism that lead to disease as well as control of infec-
tion are key questions for research in this ﬁeld. In this review, we discuss immunological
events described in human and experimental VL and how these can affect the outcome of
infection.
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VISCERAL LEISHMANIASIS
Visceral leishmaniasis (VL) is a vector borne disease transmitted
by sandﬂies (of the genus Phlebotomus in Africa, Asia, and Europe
and the genus Lutzomyia in the Americas). Unlike most human
pathogenic Leishmania species, which reside in macrophages of
the skin and skin draining lymph nodes, Leishmania donovani
and Leishmania infantum spread systemically to propagate in
macrophage of internal organs, primarily the liver, the spleen,
the bone marrow, and the lymph nodes.
Clinical presentation of VL typically involves long-term low-
grade fever, enlarged spleen and liver and weight loss, pancy-
topenia and polyclonal (IgG and IgM) hypergammaglobulinemia
(Badaro et al., 1986). Hypoalbuminemia seen in VL is associated
with edema and other features of malnutrition. Diarrhea may
occur as a result of intestinal parasitization and ulceration. Liver
function may be normal or altered and in later stages of disease
pro-thrombin production decreases. With time, untreated VL can
cause severe cachexia and bleeding due to thrombocytopenia. The
loss of thrombocytes as well as the decline in pro-thrombin can
results in severe mucosal hemorrhage that may facilitate sepsis.
Furthermore, loss of leucocytes eventually makesVL patients gen-
erally immunosuppressed, and bacterial infections are a common
cause of death in lethal cases of VL. Untreated VL will in most
cases ultimately lead to death.
The gold standard for diagnosis of all leishmaniases is demon-
stration of parasite (amastigote) in a tissue biopsy (Sundar andRai,
2002). Serological tests, such as the rk39 test (Sundar et al., 2002b),
are indicative of VL in combination with clinical symptoms, but
cannot reliably differentiate between past and recent infections.
Fortunately, most cases of VL are treatable. The drugs used
most commonly are pentavalent antimonials (SbV), Miltefosine
and Amphotericin B, all expensive and associated with toxicity. In
India resistance to SbV is wide spread (Agrawal et al., 2005) and
reports of drug resistance to other drugs, including Amphotericin
B, has been reported (Srivastava et al., 2011). At present, there
is no anti-leishmanial vaccine. Thus, there is an urgent need for
development of new therapeutic strategies.
Following therapeutic cure of VL caused by L. donovani,
patients can develop a sequel known as post kala-azar dermal
leishmaniasis (PKDL; reviewed in Ganguly et al., 2010). There
are no experimental models for this disease manifestation and
why PKDL appear is not clear. PKDL presents as appearance of
nodules, papules, and hypopigmented macules on the skin, in
which L. donovani-infected macrophage can be found (Ramesh
and Mukherjee, 1995; Zijlstra et al., 2003). In Africa, where PKDL
is more common, most of cases of PKDL heal spontaneously,
whereas in India self-cure is rare, if ever occurring (Zijlstra et al.,
2003). In line with observations of human VL (discussed below),
PKDL is associated with high level of interleukin (IL)-10 in blood
and skin during clinical disease (Gasim et al., 1998).
MODELS OF VL
Dogs, being natural host of L. infantum are highly relevant ani-
mal models for VL (Alvar et al., 2004). Notably, most L. donovani
complex infections are subclinical in both canids and humans,
but infection can in both species result in severe life-threatening
visceral disease and many features of VL are shared (Alvar et al.,
2004), while others, like the keratitis and skin pathology frequently
observed in canine VL is not seen in human disease (Baneth et al.,
2008). Due to high costs and ethical concerns dogs are only used
to a limited extent in experimental VL, small rodent models are
usually preferred.
Mouse models have been used extensively to study both L.
donovani and L. infantum infection. The outcome of murine
VL infection has a clear genetic basis; genetically resistant
mouse (e.g., CBA) has functional Slc11a1 gene that encodes
a phagosomal component, solute carrier 11a1 also know as
Nramp1, a proton/bivalent cation antiporter that localizes to
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late endosomes/lysosomes and confers the ability to control
the early infection (Crocker et al., 1984; Blackwell et al., 1989).
Susceptible strains (BALB/c and C57Bl/6) have mutant Slc11a1
gene, which allows rapid parasite replication in the liver dur-
ing the ﬁrst weeks of infection (Crocker et al., 1984; Vidal et al.,
1995). However,most susceptible mouse strains including BALB/c
acquire immune responses that control parasite growth at later
stage of infection. In these strains the rate of resolution of
disease is determined by MHC class II haplotypes (H-2 loci;
Blackwell, 1983).
Considering that “susceptible” mice control the disease, it may
be more appropriate to view the murine VL as a model for
sub-clinical or self-limiting infection rather than a model of dis-
seminated visceral disease and parallels to overt humanVL disease
should, thus, be made with caution.
In mice, immune response to L. donovani or L. infantum
infection can, within the same animal, vary markedly between
different organs (i.e., liver and spleen). Following intravenous
or intracardial infection (primarily using amastigotes), the par-
asites multiply rapidly in the liver for the ﬁrst few weeks after
which, the parasite growth is controlled by the cell-mediated
immune response and granuloma formation. Over a period of
2–3 months L. donovani-infected mice eventually clear the para-
sites from the liver and become resistant to reinfection (Murray
et al., 1987). While overt pathology is limited, the parasites persist
in the spleen and the infection slowly but continuously progress
for a longer period in the spleen as compared to the liver infec-
tion. Eventually, splenic replication is also controlled and parasites
are maintained at a constant levels (Engwerda et al., 2004). In the
spleen the persistent parasites cause splenomegaly and remod-
eling of splenic architecture with atrophy of lymphoid follicles
(Engwerda et al., 2004).
Similar to observations made in humans (see below) the
immune response in the murine spleen is characterized by a mixed
regulatory and inﬂammatory response. Both IL-10 and tumor
necrosis factor (TNF)α production is elevated in the spleen. TNFα,
which is critical for development of protective immunity in the
liver (Murray et al., 2000), cause destruction of the marginal zone
macrophages and the gp38+ stromal cells, a subset of stromal
cells conﬁned to the T cell zone of the mouse spleen. (Car-
rión et al., 2006; Stanley and Engwerda, 2007). IL-10, which has
been suggested to be induced by high levels of TNFα (Ato et al.,
2002), may serve to control the tissue damage caused by TNFα,
but the at the same time IL-10 promotes parasite persistence by
inhibiting macrophage activation (Belkaid et al., 2001). IL-10 is a
regulatory cytokine, presumed to be induced as a part of home-
ostatic network, to protect tissue from collateral damage caused
by excessive inﬂammation. IL-10 has primarily suppressive effects
on immune function, targeting multiple activation, and antigen
presentation pathways of macrophages and dendritic cells. IL-
10 renders macrophages unresponsive to activation signals and
acts on dendritic cells (DCs) causing them to down-regulate
CCR7 and thereby loosing migratory capacity preventing them
from proper accessing T cell areas and effectively priming T cells
responses (Ato et al., 2002). It has clearly been demonstrated in
mouse models that IL-10 promotes diseases progression and that
inhibition of IL-10 activity (through IL-10 receptor blockade)
leads to more rapid granuloma formation and parasite killing
(Murray et al., 2002). Blocking the IL-10R resulted in increased
IFNγ production and enhanced expression of inducible nitric
oxide synthase (iNOS) in infected tissue (Murray et al., 2003b).
Given in combination with anti-leishmanial therapy (SbV),
blockade of IL-10R was shown to enhance effectiveness of SbV
(Murray et al., 2005).
Hamsters, similar to humans and canids, can develop progres-
sive fatal disease in which parasites replicate in the liver, spleen,
and bone marrow eventually causing death of the host (Ghosh
and Ghosh, 1987; Requena et al., 2000; Melby et al., 2001). As in
humans, hamsters have up-regulated expression of Th1-associated
cytokine mRNA (IFNγ, IL-2, and TNFα in the spleen, but lim-
ited induction of IL-4 mRNA (Melby et al., 2001). Substantial
amounts of TGFβ and IL-10 mRNAs are also present, which may
promote parasite multiplication and survival. Similar to humans,
hamsters are poor producers of nitric oxide (NO). In L. dono-
vani-infected hamsters the expression of nitric oxide synthase
(NOS) 2 mRNA, the gene encoding iNOS in response to IFNγ
is not upregulated. This has been explained by reduced NOS2
promotor activity in hamster as compared to mice (Perez et al.,
2006). The failure to induce iNOS can explain the defect in par-
asite killing seen in hamsters (Melby et al., 2001; Wilson et al.,
2005). In contrast to humans, hamsters develop severe ascites and
glomerulonephritis associated with deposition of parasite antigen
immune complexes in the kidneys. The disseminated amyloidosis
and glomerulonephritis results in renal failure and nephritic syn-
drome which is causative of death in infected hamsters (Sartori
et al., 1992). Death due to renal failure is a rare event in humans
and dogs.
The lack of reagents for immunological analysis and the ani-
mal’s high innate susceptibility make hamster a less suitable model
for the evaluation of immune responses, but hamsters remain
an efﬁcient and a highly relevant model to test existing and
experimental drugs against VL.
IMMUNE RESPONSES IN HUMAN VL
Manifestations of human VL range from fatal visceral disease
to asymptomatic infection (deﬁned as presence of Leishmania-
speciﬁc antibodies or being positive skin test to Leishmania antigen
without any symptoms of VL). Whether an infection remains
asymptomatic or progressed towardVL is the results of the interac-
tions between the environment, the parasite and the host genetics,
however, what more precisely determined if a person develops VL
is at large still unclear.
Peripheral blood mononuclear cells (PBMCs) from some (but
not all) individuals with subclinical or asymptomatic infec-
tion respond to stimulation with leishmanial antigen (LAg) and
produce IL-2, IFNγ, and IL-12 (Carvalho et al., 1992). Neu-
tralizing antibodies to IL-12 abrogates both proliferation and
IFNγ production in these naturally exposed healthy individuals
(Ghalib et al., 1995).
Peripheral blood mononuclear cells from active VL patients
typically do not proliferate or produce IFNγ in response to LAg
(Sacks et al., 1987;White et al., 1992) and most patients with active
disease have a negative leishmanin skin test (LST; Manson-Bahr,
1961; Gidwani et al., 2009). A few months after completion of
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therapy, following cure, proliferative and cytokine responses to
Leishmania antigen are usually detectable (White et al., 1992). The
ability of PBMCs from curedVL patients to proliferate to Leishma-
nia antigen can be suppressed by co-culture with PBMCs from the
same patient collected prior to cure, suggesting there are immuno-
suppressive factors produced by these PBMCs (Carvalho et al.,
1989). Interestingly, recent studies using whole blood (instead
of puriﬁed PBMCs) from VL patient have shown that the blood
cells maintain to capacity to produce IFNγ in response to soluble
Leishmania antigen (Ansari et al., 2011; Gidwani et al., 2011a).
Although,VL initially was thought to be associated with a Th2-
type immune response seen as elevated levels of IL-4 and/or IL-13
(Sundar et al., 1997; Nylen et al., 2007) most studies implicate that
there is not a clear Th2 skewing in human VL. Typically VL is
associated with increased production of multiple and primarily
pro-inﬂammatory, cytokines and chemokines. VL patients have
been found to have elevated plasma protein levels of IL-1, IL-6,
IL-8, IL-12, IL-15, IFNγ inducible protein-10 (IP-10), monokine
induced by IFNγ (MIG), IFNγ, and TNFα (Ansari et al., 2006;
Kurkjian et al., 2006; Nylen et al., 2007). Elevated levels of IFNγ
mRNA has been found in the spleen and bone marrow dur-
ing the acute phase of infection (Nylen and Sacks, 2007). These
observations suggest that development of VL is not driven by
Th2 skewing per se, but that other mechanisms contribute to the
pathogenesis of VL.
In support of experimental ﬁndings, clinical studies strongly
implicates IL-10 in many of the immunologic defects associated
with kala-azar (reviewed in Nylen and Sacks, 2007). Patients with
activeVL have elevated levels of IL-10 in serum as well as enhanced
IL-10 mRNA levels in spleen, lymph nodes, and bone marrow
(Nylen et al., 2007; Ansari et al., 2011). While antigen driven IL-
10 production cannot be measured in antigen-stimulated PBMCs
from VL patients, IL-10 can be detected in whole blood cells cul-
tures ofVLpatients following stimulationwithLeishmania antigen
(Ansari et al., 2011). Further studies are needed to explain the dif-
ference in the ability of whole blood and PBMC to respond with
IL-10 production when re-stimulated in vitro.
The main disease-promoting activity of IL-10 in VL is prob-
ably conditioning host macrophages for enhanced survival and
growth of the parasite. IL-10 can render macrophages unrespon-
sive to activation signals and inhibit killing of amastigotes by
down-regulating the production of TNFα and NO. In human,
VL inhibition of IL-10 enhance the IFNγ response by antigen-
stimulated PBMC, and neutralization of IL-10 in VL serum
inhibit L. donovani replication in macrophages (Ghalib et al.,
1995; Nylen et al., 2007). A recent study from India has directly
demonstrated an anti-parasitic effect of IL-10 blockade in splenic
aspirates from patients with VL (Gautam et al., 2011). Taken
together, the data strongly support a role for IL-10 in promot-
ing pathology of VL and suggest that targeting IL-10 may be a
method to improve VL therapy and disease outcome as discussed
below.
Another cytokine implicated in the pathology of both exper-
imental and human leishmanial disease progression is TGFβ
(Barral-Netto et al., 1992; Saha et al., 2007). TGFβ has down-
modulatory effects on macrophages and its blockade has been
found to limit parasite replication in these cells (Reed, 1999;
Anderson et al., 2008). The role of TGFβ in VL is not conﬁrmed,
but anticipated to act in synergywith IL-10 as suggested formurine
cutaneous leishmaniasis (mCL).
The majority of individuals infected with L. donovani or L.
infantum never develop disease, suggesting that genetic factors
may be involved in resistance and susceptibility. Polymorphism in
SLC11a/NRAMP gene, which is linked to murine resistance, is not
clearly linked to development of disease in humans; while studies
of Sudanese populations have found an association of SLC11a gene
in regulating susceptibility with human VL (Bucheton et al., 2003;
Mohamed et al., 2004), a more recent study made in an Indian
population showed no evidence of such association (Mehrotra
et al., 2011).
Notably, environmental factors may be of equal or greater
importance. VL tends to affect poor populations with low
nutritional status and in whom gastrointestinal and helminthic
infections are common. Malnutrition can weaken both innate
immunity and T cell functions (Anstead et al., 2001; Hughes and
Kelly, 2006), and helminth exposures can shift the Th1/Th2 bal-
ance in favor of the Leishmania parasite (Hassan et al., 2006;
O’Neal et al., 2007). Hormonal changes after puberty have also
been suggested to inﬂuence susceptibility and young and adult
men are over-represented among VL patients (Jeronimo et al.,
2004; Nylen and Sacks, 2007). Experimental data on this aspect
is limited, but in support of gender-associated differences in sus-
ceptibility, male hamsters are more susceptible to L. donovani
infection (Anuradha et al., 1990) and testosterone treatment of
macrophages has been found to enhance L. donovani replication
(Liu et al., 2006).
ANTIBODIES – FRIENDS OR FOES?
The role of the anti-leishmanial antibody response seen in VL
patients is unclear. Patients with active VL have high level of
anti-leishmanial IgE, IgM, and IgG (Ghosh et al., 1995; Anam
et al., 1999; da Matta et al., 2000; Ryan et al., 2002). Moreover,
people living in endemic region are regularly bitten by Phle-
botomus argentipes and develop anti sand ﬂy salivary antibodies
(Barral et al., 2000) indicating that the sand ﬂy saliva antibody
response could beused as a tool for evaluating exposure and/or risk
of infection in endemic regions (Clements et al., 2010; Gidwani
et al., 2011c).
It has been suggested that presences of anti-leishmanial anti-
bodies could be predictive of disease (Singh et al., 2002), but this
has not been conﬁrmed. In a longitudinal serological study from
an endemic area of Bihar state, India, where 33% of individuals
were serological positive, only 3.5% of the seropositive individual
converted to disease. The conversion rate in the seronegative group
was not different (2.6%) during the 2 years of follow-up, implying
that serological status in healthy individuals cannot predict the
disease conversion (Gidwani et al., 2009; Ostyn et al., 2011).
While still limited in ability to distinguish between active and
past or subclinical infection, antibodies have proven useful in diag-
nosis of VL disease (Sundar et al., 2002a; Sundar and Rai, 2002;
Clements et al., 2010; Gidwani et al., 2011c). Apart from this, B
cells and antibodies have historically not been considered to be of
much importance in Leishmania infection. High levels of Leishma-
nia-speciﬁc antibodies are observed in patients with VL, whereas
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CL patients lack Leishmania-speciﬁc antibodies or mount a very
weak response. Thus, development of a strong humoral response
is more associated with pathology than protection or resolution
of disease (Galvao-Castro et al., 1984).
In mice, there are accumulating evidences that B cells and anti-
bodies contribute to the VL pathology (Ronet et al., 2008; Deak
et al., 2010). Mice lacking B cells were found to be less susceptible
to L. donovani infection (Smelt et al., 2000) and in cutaneousmod-
els of leishmaniasis, immune complex formation and engagement
of Fc-receptors have been found to promote parasite replication
by driving IL-10 production in macrophages (Kane and Mosser,
2001; Buxbaum and Scott, 2005). IL-10 promotes the B cells sur-
vivals and plasma cells proliferation and also IgG isotype switch
toward IgG1 and IgG3 (Caldas et al., 2005). Thus, high antibody
titers and immune complex formation inVL may contribute to the
elevated IL-10 levels observed and participate in the progressive
decline in the immune status of VL patients.
However, a protective role of antibodies cannot be excluded.
There is a high prevalence of seropositive healthy individuals in
areas endemic for VL (Costa et al., 2002) and antibodies against
Leishmania persist for a long time (15 years or more) after cure
and presumed immunity to VL (Gidwani et al., 2011b). Pres-
ence of B cells and uptake of promastigotes through FcγRI on
DC have, in mCL, been show to facilitate generation of protec-
tive T cell immunity (Scott et al., 1986; Woelbing et al., 2006).
If this holds true in experimental VL is yet to be demonstrated.
The requirement for B cell is not corroborated by the above-
mentioned study by Smelt et al. (2000) showing thatmice lackingB
cells are highly resistant to experimental VL, nor supported by the
recent study by Bankoti et al. (2012) suggesting that marginal zone
B cells suppress protective T cells responses in the early stages of
experimental VL.
PROTECTIVE Th17 CELLS?
A protective role for Th17 cells in human VL was suggested by
a recent longitudinal study carried out in the Sudan, showing
correlation between the presence of L. donovani-speciﬁc T cells,
secreting IL-17 and IL-22, and protection against developing VL
(Pitta et al., 2009).
Th17 cells are primarily pro-inﬂammatory CD4 T cells that
have the potential to secrete the prototypic cytokine IL-17
and express the transcription factors: related orphan recep-
tor (ROR)γT and signal and transduction activator of tran-
scription (STAT)-3. IL-17 act as a classic effector of innate
immunity and induces expression of many innate inﬂamma-
tory mediators, including IL-6, acute phase proteins, gran-
ulocyte colony stimulating factor (G-CSF), and prostaglandin
E2, as such Th17 cells have been implicated in a number of
immune-mediated disorders (reviewed in Tesmer et al., 2008).
Activation of Th17 cells is intimately associated with recruit-
ment of neutrophils, which may contribute to both protective
and damaging aspects of Th17 cells. In human muco-cutaneous
leishmaniasis there are implications of Th17 cells and neutrophils
in pathological responses and destruction of tissue (Boaventura
et al., 2010).
IL-27 is a cytokines central in regulation of Th17 cells, which
mainly is produced by antigen-presenting cells. Studies in mice
have demonstrated that IL-27 can inhibit the differentiation of
Th17 cells involved in autoimmunity and pathogenic responses to
infection (Batten et al., 2006; Stumhofer et al., 2006). In humans,
IL-27 suppress IL-17 and IL-22 secretion by CD4 T cells cultured
under Th17 polarizing conditions (Murugaiyan et al., 2009). In a
recent study of IndianVL it was shown that patients with on-going
disease had elevated IL-27 serum levels and increased expression
of IL-27 transcripts (EBI-3 and IL-27p28) in splenic aspirates,
while IL-17/RORγT transcripts were expressed in scarcity in the
splenic biopsies both pre- and post- treatment (Ansari et al., 2011).
Experimentally, IL-27wasmoreover found to regulate thedifferen-
tiation and expansion of antigen-speciﬁc IL-10 producing T cells
(Ansari et al., 2011). In light of the prospective study carried out
in the Sudan, implicating the protective role for Th17 cells (Pitta
et al., 2009), the low expression of Th17-associated cytokines and
transcription factors in patients with active VL combined with
up-regulation of IL-27 implicate a role for IL-27 in VL patho-
genesis. We suggest that IL-27 promote the differentiation and
expansion of antigen-speciﬁc, IL-10 producing T cells and inhibit
the potentially protective Th17 lineage and thereby facilitate par-
asite survival (Figure 1). However, it cannot be excluded that the
reduction of Th17 seen in VL is an attempt of the body to con-
trol the pathological effects of Th17 cells and the inﬂammatory
response driven by the parasite.
REGULATORY T CELLS FAVOR PARASITE
PERSISTENCE IN VL
The regulatory T cells (Treg) are broadly divided into CD4+
CD25+Foxp3+ natural Treg (nTreg) and CD4+CD25−Foxp−
adaptive Treg or Tr1 cells. In humans, this division becomes
more difﬁcult since Foxp3 expression is inducible (Roncador et al.,
2005). In mice, nTregs are generated during thymic development,
whereas adaptive Treg arises during an encounter with antigen in
the periphery. Natural Treg constitute 5–10% of peripheral CD4
T cells in human and naive mice and suppress several potentially
tissue damaging effects in vivo. The absence of Treg is associated
with a number of auto-immune conditions (reviewed in Maloy
and Powrie, 2001).
Natural Treg cells have been shown to produce high amount
of IL-10 and/or TGFβ, which in mCL contributes to the inabil-
ity to complete eliminate L. major from skin after clinical cure
(Belkaid et al., 2002). In humans, accumulation of Foxp3+ cells
have been found in the skin of L. braziliensis patients (Campanelli
et al., 2006) and patients suffering fromPKDL (Katara et al., 2011).
In both human and murine VL there is little support for accumu-
lation or extensive activation of nTreg. In our studies conducted
on patients from Bihar, India we could not reveal a major role
of natural FoxP3+ Treg cells in overt human VL disease (Nylen
et al., 2007; Maurya et al., 2010). There was no accumulation of
these cells in the VL spleen, nor were their frequency changed
after the treatment. Furthermore, Foxp3−CD4+ cells were found
to be the major source of elevated IL-10 mRNA in spleen of VL
patient (Nylen et al., 2007), supporting ﬁndings in murine mod-
els of VL showing that IL-10 production by CD4+FoxP3− cells
strongly correlate with disease progression (Stager et al., 2006).
Yet, other groups suggest that Foxp3+ cells accumulate at the
site of infection and play a role in both murine and human VL
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FIGURE 1 | Regulatory feedback loop facilitate parasite persistence. (1)
ActivatedT cells both CD4 and CD8 produce IFNγ, which in combination with
IL-1β drives IL-27 production by macrophages. (2a) IL-27 inhibits generation of
potentially protective Th17 cells and (2b) promotes together with IL-21 the
generation IL-10 secreting T cells. (3) IL-10 cause down-regulation of IL-12,
MHC class II as well as co-stimulatory molecules on macrophages and render
macrophage unresponsive to activation signals such as IFNγ. Together this
facilitates parasite replication and disease progression.
(Rodrigues et al., 2009; Rai et al., 2012). Rai et al. (2012) argue that
FoxP3+ T cells are an important source of IL-10 in human VL
and that these cells suppress effector T cell activation. Rodrigues
et al. (2009) found TGFβ producing FoxP3+ T cells accumulating
at sites of infection in experimental murine VL. Noteworthy, in
both these studies non-Foxp3+ cells were found to be a source
of IL-10 and while FoxP3 cells were in higher frequency in the
bone marrow of VL patients (as compared to their PBMC), no
signiﬁcant difference in frequency of FoxP3 cells were detected
pre-treatment as compared to post-treatment in either organ
(Rai et al., 2012).
We believe, and most scientiﬁc data point to, that parasite
driven adaptive Treg or Tr1 cells are more important than nTreg
cells in suppressing anti-leishmanial immunity in VL.
CD8 T CELLS IN VL
CD8 T cells have the capacity to directly lyse pathogen-infested
cells and can produce high levels of the macrophage activating
cytokine IFNγ. Like CD4 cells, CD8 cells subsets have regulatory
capacity, which can serve to control tissue damages, but in that
capacity may also promote parasite replication. As such, CD8
T cells may contribute to both cure and pathology in VL. In
cutaneous forms of leishmaniasis CD8 cells have been associated
with both tissue damage, as seen inmuco-cutaneous lesions (Brod-
skyn et al., 1997; Tuon et al., 2008) and by cure, seen as an increase
in the ability of CD8 cell from cutaneous L. braziliensis patients
to respond to Leishmania in vitro (Da-Cruz et al., 1994; Coutinho
et al., 1998). A lower CD4/CD8 ratio has been described in VL
PBMC (Rohtagi et al., 1996; Taher et al., 2009). The alterations in
blood cannot simply be explained by a preferential recruitment
of CD4 T cells to the spleen since, in the early stages of human
disease, VL is associated with a splenic inﬂux of both CD4 and
CD8 T cells (Nylen et al., 2007), implicating that CD8 cells may
survive better than CD4 cells in VL patients. In the end stage of
disease leukocytes are scanty and plasma cells and macrophages
predominate in the spleen (Veress et al., 1977).
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Experimental mouse models of VL show that CD8 T cells are
important in control of L. donovani/L. infantum infection in the
liver, through their ability to produce IFNγ and/or their cytolytic
activity (Stern et al., 1988; Tsagozis et al., 2003, 2005; Polley et al.,
2006). Moreover,CD8T cells are, togetherwithCD4 cells, required
to control and prevent reactivation of VL in mice (Murray, 2005).
CD8 T cell responses also provide a good correlate of immunity
following vaccination (Stager et al., 2000).
CD8 T cells activated during Leishmania infections may not all
be parasite-speciﬁc, as uninfected DCs that have matured during
inﬂammation, can stimulate CD8 T cells to proliferate without the
expression of their cognate ligands (Maroof et al., 2009). The role
of these non-leishmanial-speciﬁcCD8Tcells in the infection is not
clear. It has been shown that pre-existing memory CD8 T cells are
expanded during L. donovani infection, and that they can provide
increased resistance to previously encountered pathogens (Polley
et al., 2005). However, bystander activated CD8 T cells cannot
confer protection againstVL, as only CD8 cell recognizing cognate
antigenwere found to be protectivewhen given as immunotherapy
(Polley et al., 2006).
Leishmania donovani seem to be able to elude the expansion
of parasite-speciﬁc CD8 T cells by causing exhaustion and death
of CD8 T cell (Joshi et al., 2009). Blockade of B7-H1, the ligand
for the inhibitory receptor PD-1, was found to increase survival of
CD8 cells and induce protective immunity, suggesting that block-
ade of inhibitor receptors as immune therapy in VL (Joshi et al.,
2009). Although, the parasite have means to limit T cells response
in murine VL, the mice ultimately control the disease and CD8
cells are important in the hepatic control of parasite propaga-
tion. In mice, formation of granulomas is central in control of
the parasite in the liver. Kupfer cells inﬁltrating the granuloma
have the ability to harbor amastigotes and present antigen (You
et al., 2008; Beattie et al., 2010). In vivo imaging has revealed that
these infected Kupfer cells interact closely with antigen-speciﬁc
CD8 T cells and facilitate accumulation of effector CD8 T cells
within the liver granuloma (Beattie et al., 2010). CD8 T cells are
not well described in human VL and their functions are at large
unknown.
IMMUNOTHERAPY TO IMPROVE TREATMENT
EFFICACY
Despite signiﬁcant advances in the treatment of VL, conventional
chemotherapy is associated with toxicity and relapse of disease.
Immunotherapeutic strategies, aimed to strengthen Leishmania-
speciﬁc immune response, prior to or in synergywith conventional
therapy, may lower the required dose or treatment regimen
and thus toxicity. Immunotherapy may also improve the drug
efﬁcacy, reduce emergence of drug resistant strains, and cir-
cumvent the problems of treatment in immuno-compromised
hosts.
Attempts to identify cytokines, which may be useful in VL
therapy, have focused on cytokines thought to act on the balance
between Th1 and Th2 cells. This despite the lack of evidence for
a clear role for Th2 cells in pathology of symptomatic human VL
(Carvalho et al., 1994; Ghalib et al., 1995).
The combination of IFNγ and SbV therapy has shown ben-
eﬁcial effects in treatment of patients with VL and diffuse
cutaneous leishmaniasis (DCL; Badaro and Johnson, 1993). How-
ever, targeting regulatory pathways and cytokines may prove more
efﬁcient than boosting effector cytokines. Clinical and experimen-
tal data suggest IL-10 as a key target for VL immunotherapy.
By inhibiting IL-10, the balance between effector and regula-
tory cytokines may be shifted. IL-10 blockade may enhance
the function of antigen-presenting cells and moreover increase
the ability of infected macrophage to respond appropriately
to IFNγ, thus promoting the killing of parasite, as shown in
vitro (Nylen et al., 2007; Gautam et al., 2011). This may reduce
the dose and/or length of treatment the patients receive. Neu-
tralization of IL-10 has been tested in patients with systemic
lupus erythematosus (SLE), an immune complex disorder. In
these patients anti-IL-10 treatment decreased disease activity and
restored impaired T lymphocyte function (Llorente et al., 2000).
As stated above, in ex vivo cultures of splenic aspirates from
patients with VL, the presence of anti-IL-10 antibody was shown
to promote the killing of parasite and signiﬁcantly increased
IFNγ and TNFα secretion by spleen cells (Gautam et al., 2011).
These ﬁndings clearly demonstrate the potential beneﬁts of IL-
10 inhibition as a therapeutic approach in human VL. Other
potential targets could be receptors expressed on Treg or their
corresponding ligands on effectors cells, such as PD-1, it’s lig-
ands PD1-L (B7-H1) or CTLA-4. Targeting these regulatory
pathways has proven effective in experimental VL (Murray et al.,
2003a; Joshi et al., 2009). If these molecules are implicated in
human VL and could serve as putative targets remain to be
demonstrated.
CONCLUDING REMARKS
Failure to eliminate or control parasite replication results in con-
tinuous parasite driven immune activation and production of
pro-inﬂammatory molecules. These pro-inﬂammatory molecules
will, if not controlled, cause tissue damage and need to be tightly
regulated. As a self-regulating negative feedback mechanism many
pro-inﬂammatory molecules induce regulatory responses. We
envisage that parasite induced IFNγ, in combination with IL-
1β, act on DCs and macrophages to promote production of
IL-27. IL-27, in turn, block generation of potentially protec-
tive Th17 cells and facilitates generation of IL-10 producing T
cells (depicted in Figure 1). IL-10 effectively down-regulates
the antigen-presenting capacity both of DC and macrophages
and impairs the ability of macrophages to respond to activation
signals. While the generation of regulatory response temporar-
ily reduces tissue damage, they simultaneously allow parasite
propagation. Parasite persistence result in a continued pro-
inﬂammatory response creating a loop that causes exhaustion of
the immune system and failure to generated appropriate CD4 T
cell responses. By temporarily breaking the regulatory feedback
loop, using immune modulatory therapies to treat VL, the bal-
ance may be shifted allowing macrophage activation, killing of
the parasite and generation of curing and protective CD4 T cell
response.
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